DE60127410D1 - Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen - Google Patents

Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen

Info

Publication number
DE60127410D1
DE60127410D1 DE60127410T DE60127410T DE60127410D1 DE 60127410 D1 DE60127410 D1 DE 60127410D1 DE 60127410 T DE60127410 T DE 60127410T DE 60127410 T DE60127410 T DE 60127410T DE 60127410 D1 DE60127410 D1 DE 60127410D1
Authority
DE
Germany
Prior art keywords
calcium channel
epoxy
combination therapy
treatment
heart failure
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE60127410T
Other languages
English (en)
Other versions
DE60127410T2 (de
Inventor
Joseph R Schuh
Susan Garthwaite
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmacia LLC
Original Assignee
Pharmacia LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia LLC filed Critical Pharmacia LLC
Publication of DE60127410D1 publication Critical patent/DE60127410D1/de
Application granted granted Critical
Publication of DE60127410T2 publication Critical patent/DE60127410T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
DE60127410T 2000-07-27 2001-07-27 Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen Expired - Fee Related DE60127410T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22135900P 2000-07-27 2000-07-27
US221359P 2000-07-27
PCT/US2001/023677 WO2002009761A2 (en) 2000-07-27 2001-07-27 Epoxy-steroidal aldosterone antagonist and calcium channel blocker combination therapy for treatment of congestive heart failure

Publications (2)

Publication Number Publication Date
DE60127410D1 true DE60127410D1 (de) 2007-05-03
DE60127410T2 DE60127410T2 (de) 2007-12-13

Family

ID=22827483

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60127410T Expired - Fee Related DE60127410T2 (de) 2000-07-27 2001-07-27 Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen

Country Status (10)

Country Link
US (2) US20020042405A1 (de)
EP (1) EP1303305B1 (de)
JP (1) JP2004505061A (de)
AT (1) ATE357257T1 (de)
AU (2) AU7804501A (de)
CA (1) CA2415826A1 (de)
DE (1) DE60127410T2 (de)
ES (1) ES2281431T3 (de)
HK (1) HK1051651A1 (de)
WO (1) WO2002009761A2 (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7393652B2 (en) * 2000-05-10 2008-07-01 The Trustees Of Columbia University In The City Of New York Methods for identifying a chemical compound that directly enhances binding of FKBP12.6 to PKA-phosphorylated type 2 ryanodine receptor (RyR2)
US20040229781A1 (en) * 2000-05-10 2004-11-18 Marks Andrew Robert Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias
US20040048780A1 (en) * 2000-05-10 2004-03-11 The Trustees Of Columbia University In The City Of New York Method for treating and preventing cardiac arrhythmia
US8022058B2 (en) 2000-05-10 2011-09-20 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6489125B1 (en) * 2000-05-10 2002-12-03 The Trustees Of Columbia University In The City Of New York Methods for identifying chemical compounds that inhibit dissociation of FKBP12.6 binding protein from type 2 ryanodine receptor
US20060293266A1 (en) * 2000-05-10 2006-12-28 The Trustees Of Columbia Phosphodiesterase 4D in the ryanodine receptor complex protects against heart failure
US7718644B2 (en) * 2004-01-22 2010-05-18 The Trustees Of Columbia University In The City Of New York Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof
US7879840B2 (en) * 2005-08-25 2011-02-01 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
US6852737B2 (en) 2001-08-06 2005-02-08 Recordati Ireland Limited Crude and crystalline forms of lercanidipine hydrochloride
EP1426051B1 (de) * 2001-09-11 2008-07-16 Asahi Kasei Pharma Corporation Medizinische zusammensetzung zur prävention oder behandlung von zerebrovaskulären störungen
US8822473B2 (en) * 2002-05-21 2014-09-02 Gilead Sciences, Inc. Method of treating diabetes
AU2003248558B8 (en) * 2002-05-21 2009-07-09 Gilead Sciences, Inc. Method of treating diabetes
US7544678B2 (en) * 2002-11-05 2009-06-09 The Trustees Of Columbia University In The City Of New York Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2)
NZ540845A (en) 2002-12-24 2008-02-29 Sankyo Co Optically active dihydropyridine derivative
DK1628663T3 (da) * 2003-05-15 2010-03-08 Roskamp Res Llc Fremgangsmåde til fremstilling af medikamenter til reduktion af amyloid-aflejring, amyloid-neurotoksicitet og mikrogliose
KR101233711B1 (ko) * 2003-08-25 2013-02-18 뉴론 파마슈티칼즈 에스. 피. 에이. 항염증제로서 유용한 알파-아미노아미드 유도체
US8710045B2 (en) * 2004-01-22 2014-04-29 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the ryanodine receptors
US20100222406A1 (en) * 2007-09-11 2010-09-02 University Of Virginia Patent Foundation T Type Calcium Channel Blockers and the Treatment of Diseases
CA2576186A1 (en) * 2004-08-20 2006-03-02 University Of Virginia Patent Foundation T type calcium channel blockers and the treatment of diseases
US7704990B2 (en) * 2005-08-25 2010-04-27 The Trustees Of Columbia University In The City Of New York Agents for preventing and treating disorders involving modulation of the RyR receptors
PE20070427A1 (es) * 2005-08-30 2007-04-21 Novartis Ag Compuestos derivados de benzimidazoles sustituidos como inhibidores de tirosina quinasas
US8251998B2 (en) * 2006-08-16 2012-08-28 Biomet Sports Medicine, Llc Chondral defect repair
JP2010513325A (ja) * 2006-12-21 2010-04-30 アルファファーム ピーティーワイ リミテッド 医薬組成物
EP2117550A1 (de) * 2007-02-13 2009-11-18 CV Therapeutics Inc. Verwendung von ranolazin zur behandlung nicht-koronarer mikrovaskulärer erkrankungen
CA2678319A1 (en) * 2007-02-13 2008-08-21 Cv Therapeutics, Inc. Use of ranolazine for the treatment of coronary microvascular diseases
US20090111826A1 (en) * 2007-02-13 2009-04-30 Louis Lange Use of ranolazine for the treatment of cardiovascular diseases
CA2678272A1 (en) * 2007-02-13 2008-10-02 Cv Therapeutics, Inc. Use of ranolazine for the treatment of cardiovascular diseases
US20080233191A1 (en) * 2007-03-22 2008-09-25 Brent Blackburn Use of ranolazine for elevated brain-type natriuretic peptide
CA2689633A1 (en) * 2007-05-31 2008-12-11 Cv Therapeutics, Inc. Use of ranolazine for elevated brain-type natriuretic peptide
US20100093810A1 (en) * 2007-10-05 2010-04-15 Alzheimer's Institute Of America, Inc. Pharmaceutical Compositions for Reducing Amyloid Deposition, Amyloid Neurotoxicity, and Microgliosis
CA2701620C (en) * 2007-10-05 2014-12-09 Alzheimer's Institute Of America, Inc. Method for reducing amyloid deposition, amyloid neurotoxicity, and microgliosis with (-)-nilvadipine enantiomer
WO2010007176A1 (en) * 2008-07-17 2010-01-21 INSERM (Institut National de la Santé et de la Recherche Médicale) Inhbitors of mrp4 and agents stimulating mrp4 activity for the treatment of cardiac disorders
TWI508726B (zh) 2009-12-21 2015-11-21 Gilead Sciences Inc 治療心房纖維性顫動之方法
WO2011109262A2 (en) 2010-03-01 2011-09-09 Tau Therapeutics Llc Cancer diagnosis and imaging
CN108727453A (zh) * 2017-04-20 2018-11-02 华东理工大学 新型pd-1抑制剂及其应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040255A2 (en) * 1995-06-07 1996-12-19 G.D. Searle & Co. Method to treat cardiofibrosis with a combination therapy of an angiotensin ii antagonist and an epoxy-steroidal aldosterone antagonist
ES2167571T3 (es) * 1995-06-07 2002-05-16 Searle & Co Terapia de combinacion de antagonista de aldosterona epoxi-esteroideo y antagonista de angiotensina ii para el tratamiento del fallo cardiaco congestivo.
EP1126880A2 (de) * 1998-11-06 2001-08-29 G.D. SEARLE & CO. Kombinationstherapie von angiotensin-konvertierendem enzym hemmer und aldosterone antagonist zur reduzierung des erkrankungs- und todesfallrisikos von kardiovaskuläre erkrankungen
CA2409437A1 (en) * 2000-05-11 2001-11-22 Pharmacia Corporation Aldosterone antagonist composition for release during aldosterone acrophase

Also Published As

Publication number Publication date
HK1051651A1 (en) 2003-08-15
AU2001278045B2 (en) 2006-08-03
WO2002009761A2 (en) 2002-02-07
US20030055027A1 (en) 2003-03-20
EP1303305A2 (de) 2003-04-23
ES2281431T3 (es) 2007-10-01
WO2002009761A3 (en) 2003-01-03
ATE357257T1 (de) 2007-04-15
JP2004505061A (ja) 2004-02-19
CA2415826A1 (en) 2002-02-07
WO2002009761A9 (en) 2003-07-10
EP1303305B1 (de) 2007-03-21
DE60127410T2 (de) 2007-12-13
AU7804501A (en) 2002-02-13
US20020042405A1 (en) 2002-04-11

Similar Documents

Publication Publication Date Title
DE60127410D1 (de) Kombinationstherapie mit epoxy-steroidalen aldosteronantagonisten und kalziumkanalblocker zur behandlung von kongestivem herzversagen
BRPI0408362A (pt) combinação de um antagonista de receptor de aldosterona e um agente antidiabético
ATE330633T1 (de) Epoxy-steroidaler aldosteronantagonist und beta- adrenergischer antagonist-kombinationstherapie zur behandlung von kongestivem herzversagen
MXPA05010507A (es) Combinacion de un antagonista del receptor de aldosterona y un agente antiobesidad.
LV12639B (lv) Bifenilsulfonamidi ka duali angiotenzina un endotelina receptoru antagonisti
EA201200954A1 (ru) Способ получения полугидрата гидрохлорида (r)-8-хлор-1-метил-2,3,4,5-тетрагидро-1н-3-бензазепина, фармацевтическая композиция на его основе и его применение
EA200400146A1 (ru) Замещённые анилиновые пиперидины в качестве селективных антагонистов mch
DK0831910T3 (da) Kombinationsterapi med epoxy-steroid aldosteronantagonist og angiotensin II-receptorantagonist til behandling af kongestivt hjertesvigt
DK0831911T3 (da) Kombinationsterapi til behandling af kongestivt hjertesvigt med spironolacton og angiotensin II-antagonist
PL369887A1 (en) Pharmaceutical nanoparticulate composition of a tachykinin receptor antagonist
DE69936100D1 (de) Somatostatin-analoge mit einer zyklisierten konformationsbeschränkten hauptkette
EA200870517A1 (ru) Новые антагонисты мсн-рецепторов
DK1828177T3 (da) Hidtil ukendte MCH-receptorantagonister
EA200501075A1 (ru) Лекарственное средство для профилактики и лечения артериосклероза и гипертензии
WO2002060392A3 (en) Use of gal3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
EA200301223A1 (ru) Лекарственные формы окскарбазепина
EA200500156A1 (ru) Спироциклические пиперидины, используемые в качестве антагонистов мкг1, и их применения
MY127120A (en) A1 adenosine receptor antagonists
HU0104085D0 (en) Method for the treatment of pulmonary hypertension
ATE324890T1 (de) Zusammensetzung enthaltend einen angiotensin-ii- rezeptor-antagonist und einen diuretikum und deren verwendung zur behandlung von bluthochdruck
WO2005040157A3 (en) Novel mch receptor antagonists
TNSN04024A1 (en) Novel crystalline polymorphic forms of lercanidipine hydrochloride and process for their preparation
EA200501122A1 (ru) Замещенные алкиламидопиперидины
IL145645A0 (en) N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists
BR0011122A (pt) Antagonistas de receptor il-8

Legal Events

Date Code Title Description
8327 Change in the person/name/address of the patent owner

Owner name: PHARMACIA CORP., NORTH PEAPACK, N.J., US

8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee